Intermittent fasting on a GLP-1: what the trials and labels say

Reviewed 13 sourcesPublished by PepVault

Intermittent fasting on a GLP-1: what the fasting trials found, why no trial has tested the pair, and what the labels say on blood sugar, fluids and protein.

Hands in teal sleeves setting a plate of grilled chicken, salad and quinoa on a wooden table
Last reviewed
Sources
13
Questions
7
Compounds
3

The short answer

Intermittent fasting means eating inside a daily window, such as 16:8, or eating very little on set days, as in 5:2 or alternate-day fasting. On its own it loses about as much weight as cutting calories every day. As of November 2026 no trial has tested it with a GLP-1, so the labels guide the plan: low blood sugar with insulin or sulfonylureas, fluids, and enough protein.

Every number checked at its primary source · · 13 sources · How we research

Evidence: Randomised trials of fasting alone (12 weeks to 12 months) and a 2025 network meta-analysis of 99 trials; no human trial of fasting with a GLP-1 for weight loss as of November 2026, one Ramadan trial of liraglutide in type 2 diabetes, a mouse study and one case report; semaglutide, tirzepatide and liraglutide are FDA-approved.

Hands in teal sleeves setting a plate of grilled chicken, salad and quinoa on a wooden table

What is intermittent fasting?

It is any eating plan built on when you eat rather than only on what you eat. The trials test three main patterns, and they are different enough that a result for one does not carry over to the others.

PatternWhat it meansAs tested in trials
Time-restricted eating (16:8 and similar)All food inside a daily window; nothing with calories outside itEating from noon to 8 p.m.23, or from 8 a.m. to 4 p.m. with a calorie cap1
5:2Two low-calorie days a week, usual eating on the other five500 to 600 kcal on 2 days that are not back to back5
Alternate-day fastingFast days and normal days take turns25% of energy needs on fast days, 125% on the days between4

A GLP-1 medicine, such as semaglutide (Wegovy, Ozempic) or tirzepatide (Zepbound, Mounjaro), works from the other side. It copies a gut hormone that slows the stomach and quiets hunger, so many people eat less without planning to. The 2025 nutrition advisory for people on these medicines has a name for it: unintended intermittent fasting, from simply not being hungry7.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

On a weekly GLP-1, PepVault's Food page compares what you eat in the 3 days after a logged shot with your other days over the last 30 days, protein included, once it has 3 logged days of each.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Does intermittent fasting work better than cutting calories?

Not in the long trials. When fasting and daily calorie cutting go head to head for a year, people lose about the same. Fasting is a way to eat less, and it works when it does that.

TrialWho and how longFasting groupComparison group
Liu 2022, time-restricted eating plus a calorie cap139 adults with obesity, 12 months−8.0 kg−6.3 kg on the calorie cap alone; no significant difference1
Lin 2023, noon to 8 p.m., no calorie counting90 adults with obesity, 12 months−4.61 kg against controls−5.42 kg against controls on a 25% daily calorie cut; no significant difference3
TREAT 2020, noon to 8 p.m.116 adults with overweight or obesity, 12 weeks−0.94 kg−0.68 kg on three set meals; no significant difference2
Trepanowski 2017, alternate-day fasting100 adults with obesity, 12 months−6.0% of body weight against controls, 38% dropped out−5.3% against controls on a daily cut, 29% dropped out; no significant difference4
Carter 2018, 5:2137 adults with type 2 diabetes, 12 months−6.8 kg, HbA1c −0.3%−5.0 kg, HbA1c −0.5% on a daily cut; no significant difference5

The widest look so far is a 2025 network meta-analysis in the BMJ: 99 randomized trials in 6,582 adults. Every fasting plan and daily calorie cutting beat eating freely. Only alternate-day fasting beat daily calorie cutting, by 1.29 kg, and in trials of 24 weeks or longer no plan beat another6. HbA1c, the three-month blood sugar average, did not differ between plans6.

Has any trial tested intermittent fasting with a GLP-1?

No human trial has tested the pair for weight loss as of November 2026. A search of PubMed and ClinicalTrials.gov finds one trial that comes close: IMPACT-ADT, a phase 2 study in 60 men on hormone therapy for prostate cancer. It puts time-restricted eating, semaglutide or tirzepatide, and a heart-healthy diet in three separate groups, set against each other and never taken together. It is recruiting and expected to finish in 20288.

The nearest result is in mice. Obese female mice on tirzepatide lost more weight when their food was limited to a 12-hour window, and more again with stair-climbing resistance training added, which also raised muscle mass9. That was in mice, over 8 weeks, and has not been repeated in people.

The best human data on fasting while on a GLP-1 come from Ramadan, when people fast from dawn to sunset for a month. In LIRA-Ramadan, adults with type 2 diabetes on metformin either switched to liraglutide, a daily GLP-1, or stayed on a sulfonylurea, an older pill that pushes insulin out whatever the blood sugar. Documented symptomatic low blood sugar was reported in 2% on liraglutide (3 people) and 11% on the sulfonylurea (18 people), with no severe episodes in either group10.

That fits how a GLP-1 works: it raises insulin in a glucose-dependent way, mainly when blood sugar is high11. It is why the labels tie the larger risk of low blood sugar to the medicines given alongside it, insulin and the sulfonylureas1112.

What do the GLP-1 labels say that matters for fasting?

The labels set no meal timing for the weekly shots: Wegovy and Zepbound go in once a week, at any time of day, with or without meals1112. The daily Wegovy tablet is the exception: it is taken on an empty stomach in the morning, with up to 4 ounces of water, and food waits at least 30 minutes11. Three of their warnings matter more when you eat less often.

  • Low blood sugar. On the Zepbound label (revised August 2026), low blood sugar (a reading under 54 mg/dL) in people with type 2 diabetes was 4.2% on the drug against 1.3% on placebo, and 10.3% in those also taking a sulfonylurea against 2.1% without one. In people without diabetes, where low blood sugar was not tracked systematically, a reading under 54 mg/dL turned up in 0.3%, against none on placebo12. Both labels say a lower dose of insulin or sulfonylurea may be needed, and that the prescriber decides it1112.
  • Fluids. Kidney injury after dehydration has been reported, mostly in people with nausea, vomiting or diarrhea. The patient leaflets say drinking fluids helps lower the chance of dehydration1112. A fasting window still allows water, and the advisory lists getting enough fluids among its eating habits7.
  • Eating. Both labels pair the medicine with a reduced-calorie diet and more activity1112. The advisory adds that people who fast on a GLP-1 should still eat their meals at regular times of day, and its table lists long periods without meals, to the point of becoming overly hungry, among the habits to keep to a minimum7.

One case report shows what an extreme version looks like. A 30-year-old man without diabetes, on tirzepatide 2.5 mg a week, eating only from noon to 6 p.m. and on a strict ketogenic diet, had lost 15 pounds in 3 weeks. Treated for injuries after a motorcycle crash, he was found to have euglycemic ketoacidosis: ketones built up and made his blood acidic while his blood sugar stayed normal. Fluids and glucose corrected it within 12 hours13. His doctors write that it is unclear whether the fasting, the diet, the drug or the mix set it off, and the crash itself is a second strain on the body13.

When to get help Signs of low blood sugar, such as shakiness, sweating, confusion or a fast heartbeat, or nausea, vomiting or diarrhea that does not go away, are reasons to call your prescriber, as the labels say1112.

Does fasting on a GLP-1 cost more muscle?

Fasting alone gives a mixed signal. In TREAT, the 25 people on the noon-to-8 window who were scanned lost more appendicular lean mass, the lean tissue in the arms and legs, than the 25 on set meals2. In Liu's year-long trial, lean mass changed no differently between groups1. The advisory is plain about the risk: long periods of fasting without enough protein can lead to nutrient shortfalls, loss of fat-free mass and a lower resting metabolism, and strength training with enough protein and calories offsets it7.

How much of the weight lost on a GLP-1 is lean mass, and the protein and training figures the advisory proposes, have their own guide: Muscle on a GLP-1. The fasting-specific point is that a shorter window leaves fewer meals to fit that protein into.

Does the shot day change how fasting feels?

The drug level is not flat across the week. On the Wegovy label, semaglutide reaches its highest level 1 to 3 days after the shot11. Tirzepatide peaks a median of 24 hours after it, anywhere from 8 to 72 hours, and has a half-life of about 5 days12. The chart shows tirzepatide's weekly rise and fall.

Try it

How Tirzepatide builds up

An estimate from a half-life of about 5 days, one dose a week for four weeks. The shape of the level, not a measurement.

Try your own scheduleTirzepatide in the library

Commonly reported: the least appetite in the day or two after the shot, skipped meals that were never planned on those days, and a fast that feels easy early in the week and harder before the next shot.

So a planned fast day that lands just after the shot stacks two things that both cut intake. Protein and fluids are the two things the advisory and the labels ask you to keep up on those days71112.

On a weekly GLP-1, PepVault's Food page compares what you eat in the 3 days after a logged shot with your other days over the last 30 days, protein included, once it has 3 logged days of each. Track your food in PepVault

If you fast on a GLP-1, what should you watch?

These come from the labels and the 2025 advisory. Whether to fast, and how, is a decision to make with your prescriber.

  1. If you take insulin or a sulfonylurea, raise the fasting plan with your prescriber before day one: those are the medicines the labels name for low blood sugar, and their dose is the prescriber's call1112.
  2. Set your day's protein target first, then split it across the meals that fit in your window. A 120 g target over two meals is 60 g a meal, so each meal needs a large protein portion.
  3. Eat the protein part of each meal first, so it goes in before your appetite runs out7.
  4. Drink water through the fasting hours too, and more on days with nausea, vomiting or diarrhea1112.
  5. Keep the window at the same hours each day, as the advisory asks of people who fast on a GLP-17.
  6. Keep strength training in the week, since it is what the advisory names to protect lean mass7.
  7. Watch the days after your shot: if those days already skip meals, a planned fast on top of them can push protein and fluids too low.

PepVault's Food page sets one daily protein target from your profile and goal, and counts each meal you log against it, with a water ring you tap one glass at a time. Track your food in PepVault

Track it in the app

Sources

  1. Liu D, Huang Y, Huang C, et al. Calorie restriction with or without time-restricted eating in weight loss. N Engl J Med. 2022;386(16):1495-1504. PubMed 35443107
  2. Lowe DA, Wu N, Rohdin-Bibby L, et al. Effects of time-restricted eating on weight loss and other metabolic parameters in women and men with overweight and obesity: the TREAT randomized clinical trial. JAMA Intern Med. 2020;180(11):1491-1499. PubMed 32986097
  3. Lin S, Cienfuegos S, Ezpeleta M, et al. Time-restricted eating without calorie counting for weight loss in a racially diverse population: a randomized controlled trial. Ann Intern Med. 2023;176(7):885-895. PubMed 37364268
  4. Trepanowski JF, Kroeger CM, Barnosky A, et al. Effect of alternate-day fasting on weight loss, weight maintenance, and cardioprotection among metabolically healthy obese adults: a randomized clinical trial. JAMA Intern Med. 2017;177(7):930-938. PubMed 28459931
  5. Carter S, Clifton PM, Keogh JB. Effect of intermittent compared with continuous energy restricted diet on glycemic control in patients with type 2 diabetes: a randomized noninferiority trial. JAMA Netw Open. 2018;1(3):e180756. PubMed 30646030
  6. Semnani-Azad Z, Khan TA, Chiavaroli L, et al. Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: systematic review and network meta-analysis of randomized clinical trials. BMJ. 2025;389:e082007. Erratum: BMJ. 2025;390:r1737. PubMed 40533200
  7. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity. 2025;33(8):1475-1503. PubMed 40445127
  8. City of Hope Medical Center. IMPACT-ADT: time-restricted eating, a GLP-1 receptor agonist (semaglutide or tirzepatide) or a heart-healthy diet during androgen deprivation therapy, a phase 2 randomized study (NCT07202247). ClinicalTrials.gov, recruiting, read November 20, 2026. clinicaltrials.gov
  9. Macêdo APA, da Conceição de Mattis LR, de Lima RD, et al. Combined time-restricted feeding and resistance training enhance tirzepatide-induced improvements in adiposity and whole-body insulin sensitivity in female mice. J Physiol. 2026;604(22):9026-9044. PubMed 42958899
  10. Azar ST, Echtay A, Wan Bebakar WM, et al. Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial. Diabetes Obes Metab. 2016;18(10):1025-1033. PubMed 27376711
  11. Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information and patient information (DailyMed, revised June 2026): sections 5.4, 5.5, 12.3 and 17. dailymed.nlm.nih.gov
  12. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information and patient information (DailyMed, revised August 2026): sections 5.3, 5.7, 6.1, 12.3 and 17. dailymed.nlm.nih.gov
  13. Raptis D, Theodoropoulos P, Shah MK, Bloomgarden N, Kishore P. A case of euglycemic diabetic ketoacidosis with tirzepatide use and severe calorie restriction. JCEM Case Rep. 2026;4(2):luaf324. PubMed 41613297

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo